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Efficacy of intravenous 6-aminolaevulinic acid photodynamic therapy on
rabbit papiliomas
LA Lofgren, AM Ronn, M Nouri, CJ Lee, D Yoo and BM Steinberg
Department ofOtolaryngology, Long Island Jewish Medical Center, The Long Island Campusfor the Albert Einstein College Qf
Medicine, New Hyde Park, New York 11040, USA.
Summary Endogenously induced protoporphyrin IX (PPIX), a metabolite of 6-aminolaevulinic acid (ALA),
has been evaluated as a photosensitising agent for destruction of papillomas in cottontail rabbit
papillomavirus-infected Dutch belted and New Zealand rabbits. Three factors were evaluated: (1) relative
retention ratio of drug in normal tissue, papilloma and plasma over time; (2) tissue tolerance to treatment
factors; and (3) efficacy of treatment protocol. Three drug doses of ALA were examined: 50, 100 and
200 mg kg- '. Actual PPIX concentrations in tissue and plasma were determined spectrophotofluorometrically.
The optimal treatment time occurred 3-6 h post ALA injection. The highest PPIX concentration ratio
between papilloma and normal skin was 6:1. Different light doses were investigated, using an injection to
exposure interval of 3 h and an irradiance of 100 mW cmn' at a wavelength of 630 nm. Efficacy without risk
of significant damage to normal skin was obtained using 100-200mgkg-' ALA and 40-60Jcm-'. A
long-term (3 months) cure rate of 82% was obtained with a single treatment, provided that papilloma depth
did not exceed 8 mm, volume was not more than 1000 mm3 and the plasma concentration of PPIX
immediately before exposure was above 500fig ml '. The short time between injection and treatment and high
efficacy, together with PPIX disappearance from plasma and tissue within 24 h, make injected ALA a highly
attractive drug for photodynamic therapy.
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Photodynamic therapy (PDT) is a method for tumour
therapy based on the transferral ofelectromagnetic energy, in
the form ofvisible light, to tissues containing a photosensitis-
ing agent. An important characteristic of these agents or
drugs is the ability to convert electromagnetic energy to
chemical energy, thus transferring oxygen from the normal
triplet state to highly reactive and cytotoxic singlet oxygen.
Another important property of agents for effective tumour
photosensitisation is that they should load into, or convert
to, active metabolites to a higher degree in tumour tissue
than normal tissue. The higher the loading of the drug into
the tumour at the chosen interval in relation to the concent-
ration in normal tissue (tumour to normal tissue ratio), the
better the chance of destroying the tumour without damage
to normal tissue.
Most human PDT treatments (Marcus, 1990) have been
carried out with haematoporphyrin derivative (HPD) or
porfimer sodium (Photofrin), a standardised derivative of
HPD. Both are porphyrins derived from biological material
and have similar properties. They are injected intravenously
48-72h before treatment, to allow the drug to clear fro,p
normal tissues surrounding the tumour to be treated and
from plasma. Unfortunately, the ratio with these first-
generation drugs is, at its best, in the range of 2:1 to 4:1
(Tralau et al., 1990), requiring meticulous dosimetry for suc-
cessful tumour destruction without causing damage to nor-
mal surrounding tissue. First-generation drugs also have a
long half-life, especially in skin, and necessitate protection of
skin from sunlight for 5-16 weeks (Mullooly et al., 1990).
A number of 'second-generation' drugs have been reported
in the literature, many with shorter half-lives. One of these,
meta-tetra(hydroxyphenyl)chlorin (m-THPC), has been exten-
sively studied (Berenbaum et al., 1986; Bonnett et al., 1989;
Ris et al., 1991) and is currently in phase I-II clinical trials.
In addition to a shorter half-life, it also has the advantage of
having a tumour to normal tissue ratio of up to 10:1 (Lof-
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gren et al., 1994). The optimal interval between injection and
treatment for this drug is 4-8 days and the hypersensitivity
ofskin to sunlight is very low after 3-4 weeks. Photosensitis-
ing drugs with an even shorter interval (hours) between
administration and treatment, a short half-life, especially in
skin (hours), and a high tumour to normal tissue retention
ratio would be of considerable value if the agents were also
capable of inducing efficient tumour destruction.
It has been suggested that porphyrin precursors should be
investigated for PDT (Peng et al., 1987). 6-Aminolaevulinic
acid (ALA) is converted in vivo to protoporphyrin IX
(PPIX), a potentially good photosensitiser. PPIX is the last
product in the biosynthesis of haem before the introduction
of iron into the molecule, a step regulated by the enzyme
ferrochelatase. PPIX is also the agent causing the photosen-
sitivity in erythropoietic protoporphyria. Reports on good
clinical results in the treatment of basal cell carcinomas
(Kennedy and Pottier, 1992; Wolf et al., 1993) by applying
cold cream containing 20% 6-aminolaevulinic acid (ALA)
prompted us to ask if this substance would be effective, safe
and have a rapid clearance from plasma and tissues if
administered systemically. In addition, we intended to find
the optimal interval between injection and exposure to light
and find the optimal dose for drug and light administration.
The model system we used is cutaneous papillomas on
domestic rabbits, induced by inoculation with the cottontail
rabbit papillomavirus (CRPV). The lesions are characterised
by papillary fronds composed of hyperplastic and hyperkera-
tinised epithelium surrounding mesenchymal cores containing
newly formed capillaries (Kreider and Bartlett, 1981). The
papillomas appear 2-3 weeks after virus inoculation, grow
continuously larger with time in the majority of rabbits, and
usually persist for the life of the animal. In a subset of
rabbits (less than 5% in our studies), the lesions can spon-
taneously regress due to immune system response. They can
also progress spontaneously to malignant carcinomas (Rous
and Beard, 1935; Syverton, 1952), and thus serve as a good
model for premalignant lesions. We used a previously
reported approach to systematically evaluate photosensitising
anti-tumour agents with this animal model (Lofgren et al.,
1994) to evaluate ALA. This systematic approach determines
the optimal treatment factors (e.g. drug dose, light dose,Photodynamic therapy using injected ALA
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treatment interval) and uses these optimised factors to study
possible damage to normal tissue and the long-term efficacy
of the treatment.
Materials and methods
Rabbits and virus inoculations
Sixteen Dutch belted and six New Zealand White rabbits
with a mean body weight of 2.5 and 4.5 kg respectively were
inoculated with CRPV and used for studies of relative reten-
tion, tissue tolerance and efficacy. The smaller rabbits were
given 10-12 inoculations and the larger New Zealand White
rabbits were inoculated in up to 20 areas. The areas were
marked by tattoos before inoculation (Lofgren et al., 1994).
Between 6 and 12 weeks after inoculation, papillomas with
a base diameter of 5 to 30 mm had developed in all
inoculated areas. All experiments were approved by the Insti-
tutional Animal Care Committee and carried out under full
anaesthesia with repeated i.m. doses of 1-1.5 ml of ketamine
hydrochloride (Ketaset, Aveco, Fort Dodge, IA, USA)/
xylazine hydrochloride (Rompun, Haver, Mobay Corp.
Animal Division, Shawnee, KS, USA), mixed 2- 1.
Drug and light source
5-Aminolaevulinic acid (tissue culture tested) was purchased
from Sigma (St Louis, MO, USA). The amount required for
each animal was weighed and then dissolved in 1 N sodium
hydroxide. The solution was adjusted to a final pH of
7.2-7.4 and used immediately. Solutions of ALA in saline
are very acidic and cannot be injected without causing pain,
while neutral solutions of ALA are very unstable. Fresh
solutions have a light yellow colour while degrading solutions
are a dark yellow colour, eventually turning brown. The drug
should be used within 30 min of preparation.
Three doses of ALA were studied: 50, 100 and 200 mg
kg-' (and one experiment with 300 mg kg-'). In order to
express dose by surface area, and without such information
in the recent literature, three Dutch Belted rabbits (body
weights of 2.37, 2.04 and 2.10 kg) were measured alive (base
of tail to neck, largest circumference and foot to foot over
shoulders and hips), then killed and skinned. The skin was
pinned on a paper sheet using the prior measurements, the
borders traced with a pen and the full area measured. Skin
areas were 0.15, 0.13 and 0.13 m2 respectively; the mean skin
area = 0.14 m2. Drug concentrations were thus 785, 1570,
3140 and 4710mgm-2.
Light was generated by a Spectra-Physics argon ion (model
2016-05S) pumped dye laser (Spectra-Physics model 375)
emitting at 630 nm. A 400 tm-diameter quartz fibre with a
microlens (PDT Systems model 5010-A02) was attached via a
fibre coupler. Irradiance was kept at lOOmW cm-2. Skin
temperature does not rise above 37.2°C at this level (Lofgren
et al., 1994). Whenever the laser was on, protective goggles
were worn for eye protection.
Concentration measurements
At time points ranging from minutes to 24 h after ALA
injection, blood samples of 1-3 ml were collected and several
10-30 mg biopsies were taken from papillomas and skin. All
tissue weights in this study are wet weights. Blood was
centrifuged at 2 000 r.p.m. for 10 min, and plasma removed.
Tissues were frozen in liquid nitrogen and pulverised in a
Teflon chamber with a steel ball, using a Braun Micro
Dismembrator II (N Braun Biotech, Allentown, PA, USA).
One millilitre of dimethylsulphoxide (DMSO) was added to
every 10 mg of tissue. After rotation on a wheel for 1 h, the
suspension was centrifuged at 15 000 r.p.m. for 15 min. Sam-
ples were kept in the dark during extraction. Plasma and
tissue supernatants were excited at 390 nm in a Shimadzu
RF-540 spectrofluorophotometer with an emission range of
600-700 nm. The height of the 616 nm peak for plasma and
the 630 nm peak for tissue extracts (DMSO causes a red shift
and a somewhat amplified signal) was compared with appro-
priate PPIX (Sigma) standard curves. Standard curves were
prepared for PPIX using 0.9% sodium chloride Injection
USP (Baxter Healthcare Corporation, Deerfield, IL, USA)
and 99.9% spectrophotometric grade DMSO (Jansen Chim-
ica, Geel, Belgium) for dilution. PPIX is soluble in saline at
ngml-' to ILgml-l concentrations, and the highest concen-
tration in our standard curve was less than 1 jgml . The
identity of the PPIX was confirmed by complete absorption/
fluorescence analysis of a subset of samples. The assay tech-
nique permits an analysis of up to 40 samples per day. The
lowest detectable concentration with a reliable signal to noise
ratio was 80 ng g-' tissue.
The reliability of the extraction protcol was determined by
adding aliquots of lOOng ml-' PPIX, dissolved in double-
distilled water, to triplicate samples of pulverised normal
rabbit skin, incubating for 1 h, centrifuging, and extracting
the tissue pellet with DMSO as described above. Ninety-two
per cent of the added PPIX was recovered from the skin
samples, confirming that the extraction procedure did not
result in significant underevaluation of the tissue levels.
Stability of the PPIX was also addressed by evaluating tissue
extracts and both standard curves after storage at 4°C. They
were very stable for several weeks if kept dark.
Tissue autofluorescence
To determine whether papillomas showed autofluorescence
owing to endogenous PPIX, several were divided into three
parts with a scalpel: a highly keratinised hard top layer, a
soft whitish middle part and a firm base with a translucent
grey colour. The three layers were easily distinguished
visually. Each part underwent extraction as described above.
The autofluorescence signal appeared highest in the top layer
but was difficult to distinguish from noise caused by other
materials. The middle part always fluoresced more at the
PPIX wavelength in both injected and control animals than
the base (dermis), which usually contained very little fluores-
cing material. Measurements of drug concentration in papil-
lomas in this report were done on extracts from a centre slice
from the middle portion, correcting for autofluorescence with
values from samples obtained just before the injection of
drug.
Treatment of two non-sensitised papillomas with light
doses of 200 Jcm-2, without any effect, ruled out the pos-
sibility that ALA effects could also reflect endogenous PPIX.
Distribution ofphotosensitiser in various tissues
Two Dutch Belted rabbits (body weights of 1.89 and 2.50 kg)
were injected with 100 mg kg-' ALA. Three hours later,
blood was collected to determine the concentration of PPIX
in plasma and the animals killed with an intravenous over-
dose of pentobarbital. Two non-injected rabbits (2.37 kg and
2.43 kg) were also killed and dissected to serve as controls.
Organs were weighed and samples of tissue were taken in
dimmed light, wet weighed and frozen to - 70°C for later
measurement of PPIX concentration.
Photodegradation and reperfusion
In order to study the rate of in vivo degradation of PPIX
during treatment (photobleaching), a rabbit with papillomas
on both sides of the back was used for a time-dependent
study. Three hours after injection of 200 mg kg-' ALA,
papillomas were irradiated at 100 mW cm-2 for 10 min
(60 J cm2). One non-irradiated papilloma was used as a
control for each irradiated one. Both the treated papillomas
and their corresponding control were excised and analysed
for drug concentration at hourly intervals, with time points
ranging from 15 min to 4 h after irradiation. A total of ten
papillomas, five control and five exposed, were used.
858Tissue tolerance to treatment test
Ten rabbits were injected with 50, 100 or 200mgkg-' ALA
and exposed to incremental light doses. Each rabbit was
given 1-5 series ofexposures. Various intervals between drug
injection and exposure of the skin were used, ranging from 3
to 5 h. The rabbits were shaved on the back as described
previously (Lofgren et al., 1994). A fibre with a microlens
was used to irradiate areas of normal skin ranging in size
between 10 and 14 mm. Surrounding skin was intentionally
not protected from fluorescent room light or scattered treat-
ment light so as to mimic eventual operating room ambience.
A range of skin exposures (10, 20, 40, 80 and 160 J cm-2)
were routinely carried out. No exposures were done in areas
of black skin. The exposed skin areas were examined at least
every other day during the first week, and then at longer
intervals depending on the reaction. Photographs were taken
during examination and the skin reactions were scored as
follows:
0 No damage. Transient slight redness permitted. No scarr-
ing at any time point.
1 Slight damage. Swelling of skin with or without blanching
or redness. Barely visible scar permitted. Intradermal
petechial bleeding may occur. Occasional reduction in
thickness of dermal connective tissue, with intact epi-
thelium at all times, was acceptable. This resulted in
occasional minimal depression in exposed area.
2 Moderate damage. Destruction of skin but not full thick-
ness, resulting in a superficial scar.
3 Severe damage. Indicated by chalk-white or blue-grey
skin, resulting in thick eschar formation or deep ulcera-
tion.
Efficacy studies
A total of 154 papillomas on 21 rabbits were treated with
light doses of 40 or 60Jcm2, and two papillomas were
treated with 160 J cm-2. Papillomas ranged in size from
128 mm3 to 17 986 mm3, with all but four below 10 000 mm3.
Thickness of papillomas ranged between 3 mm and 85 mm,
with only three greater than 20 mm. All treatments were
done 3 h after ALA injection. Blood samples were taken at
the time of treatment in all but two rabbits to measure PPIX
concentration. Seventy-two papillomas were exposed to
40 J cm-' and 37 papillomas were exposed to 60 J cm-2 after
injection with 100 mgkg-' ALA. Forty-five papillomas were
treated using 200 mgkg-' ALA and a light dose of 60 J
cm-2. Normal skin surrounding the papillomas was not
masked. A minimum of a 5 mm rim of normal skin was
a b
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always exposed with the papilloma to evaluate the reaction
of normal tissue. There was no effect on the normal tissue.
One additional papilloma on each rabbit was not exposed to
light as a control to exclude regression owing to immuno-
logical response to the papillomas during the 3-month
follow-up. There was no spontaneous regression of the un-
treated papillomas.
Rabbits were examined weekly, warts measured and results
documented with 35 mm colour photographs over a period
of 3 months. Efficacy was defined by papilloma size at 3
months post PDT. Complete response (CR) was defined as
total absence of the papilloma. Partial response (PR) was
defined as a decrease in wart volume of greater than 50%. A
decrease in volume of less than 50% was defined as no
response (NR).
Results
Relative retention ratio
ALA pharmacokinetics in plasma, papilloma and normal
skin displayed rapidly rising levels of PPIX beginning
immediately after intravenous injection (Figure 1). The
highest concentration of PPIX in plasma was found 1 h after
a dose of 50 (Figure la) or 100mg kg-' (Figure Ib), and 2 h
after a dose of 200 mg kg-l (Figure lc). The plasma concen-
tration of PPIX decayed to levels close to baseline after 24 h,
regardless of the dose of ALA, with a half-life of approx-
imately 60 min.
PPIX levels in papillomas and normal skin showed a
different pattern, with a rapid rise following injection ofALA
but a slower rate of reduction. An injection of 50 mgkg-'
(Figure la) gave a maximal concentration of 1.5jig g-' papil-
loma tissue, occurring 5 h after injection. Higher concentra-
tions in papilloma (2.2-2.3fig g-1) were found after injection
of 100 mgkg-' (Figure lb) with peak levels occurring
between 3 and 4 h after injection. The highest concentration
of PPIX in papilloma (2.5-2.7 tg g-') was found 3-4 h after
injection of 200 mg kg-' body weight (Figure Ic). Concentra-
tions tended to plateau between 2 and 6h and were not
measured in the interval between 7 and 24 h. PPIX levels in
normal skin were always lower than in papilloma tissue, with
the drug concentration at baseline levels 24 h after injection.
Together, these results established an optimal treatment time
of 3-6 h post injection.
The highest relative ratio between papilloma and normal
skin (6:1) was found after an injection of 50 mgkg', while
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Figure 1 Pharmacokinetics of PPIX levels. Concentration of PPIX in plasma (circles), papilloma (triangles) and skin (squares) was
measured over time after intravenous injection of three different doses of ALA. a, 50 mg kg-'; b, 100 mg kg'- and c, 200 mg kg-'
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100 mgkg-' and 200 mgkg-' gave a maximum relative ratio
of 4:1. Higher doses of ALA increased the PPIX concentra-
tion in normal skin proportionally more than in papillomas,
thereby reducing the relative ratio and presumably also the
therapeutic ratio. However, the higher doses enhanced the
actual drug levels in the papillomas.
To evaluate the levels of PPIX in other organs at treat-
ment time, we performed a full biodistribution study in two
Dutch Belted rabbits 3 h after injection of 100 mg kg-' ALA
(Table I). The concentration of endogenous PPIX in most of
the corresponding tissues of the two control animals was
zero. Organs known to contain a large number of capillaries
and sinusoids, such as liver and spleen, had a high endog-
enous concentration of the drug. Kidney had a barely detec-
table level, whereas tissues with a comparatively sparse blood
supply, such as bone and cartilage, contained no detectable
PPIX. We postulate that the autofluorescence seen in the
middle layer of the papillomas is due to the endogenous
PPIX in erythrocytes trapped in the abundant capillaries of
these benign tumours. In fact, extraction of packed eryth-
rocytes from the non-sensitised animals gave a yield of
naturally occurring PPIX of 0.07ltg g'. There was no PPIX
in plasma from non-injected rabbits.
The highest values after injection of ALA were found in
the plasma, followed by gall bladder wall and liver. The very
high levels seen in plasma might suggest that conversion of
ALA to PPIX by reticulocytes results in a rapid transfer
from the cells to the plasma. The high liver and gall bladder
levels were not surprising, as PPIX is excreted mainly
through the liver (Schimizu, 1978). A number of tissues
contained more PPIX per gram tissue than the papillomas.
Oral mucosa and skin contained only small amounts of
PPIX, whereas muscle had a fairly high content. Biopsies
from organs such as tongue and oesophagus represented a
mixture of mucosa and muscle tissue. In terms of PDT, the
more important ratio is the concentration of drug in the
abnormal target tissue compared with the immediate sur-
rounding normal tissue. In the two animals dissected for
distribution, the ratio between papilloma and skin was only
2:1, but the average maximum ratio for all papillomas
studied with this dose was 4:1
Using data from Table I, the conversion efficiency of ALA
to PPIX can be calculated by using the following equation:
Overall conversion efficiency (19.3%) =
(C A) -(E- D) 100
B
where A is the mean weight of injected rabbits (2.2 kg), B is
the injected ALA (100 mgkg-'), C is the total PPIX
measured in injected rabbits (42.58 mg), D is the mean weight
of control rabbits (2.4 kg), E is the total PPIX measured in
control rabbits (0.06 mg).
Tissue tolerance to treatment
Normal skin response to PDT was evaluated after intra-
venous injection of 50, 100 and 200 mgkg' ALA respec-
tively, with exponentially incrementing light doses (10-160J
cm-2) 3-5 h after injection (Figure 2). No or slight damage
was noted after doses up to and including 20 Jcm-' regard-
less ofdrug dose. Moderate skin damage was seen in 3 out of
26 test areas treated with light doses of 40 or 80 J cm-2.
Severe damage with a deep eschar was seen in 1 of 13 areas
treated with 160 J cm-2. Damage tended to correlate with
light dose but not drug dose. The single score of severe
damage occurred in an animal injected with 100mgkg-',
and two of the moderate damage scores were in an animal
injected with 50 mgkg'.
Photodegradation
Table I Bioconversion of ALA to protoporphyrin IX
Tissue
Plasmaa
Gall bladder wall
Liver
Urinary bladder
Spleen
Adrenal glands
Intestine
Skeletal muscle
Heart
Kidneys
Lungs
Papilloma
Tongue
Oesophagus
Skin
Erythrocytesa
Bone marrow
Aorta
Salivary gland
Fat
Oral mucosa
Trachea
Stomach
Testes
Vena cava
Cartilage
Spinal cord
Bone
Diaphragm
Brain
conce
(AS
Injected
454.20
101.00
11.40
4.30
3.30
3.30
3.00
2.70
2.60
2.60
2.50
2.20
2.10
1.50
1.20
1.10
1.10
1.10
1.10
0.90
0.80
0.70
0.75
0.50
0.40
0.34
0.33
RPIX
entra
gg-
PPIX
tion content
') (mg per organ)
Control Injected Control
- 38.800 -
2.00 0.006 -
0.95 0.600 0.053
- 0.005 -
0.22 0.002 -
- 0.002 -
0.230 -
- 1.900 -
0.35 0.016 -
- 0.040 -
- 0.035 -
0.44 ND ND
- 0.013
0.002 -
- 0.450 -
0.07 0.041 0.003
0.13 ND ND
- ND ND
- 0.001 -
- 0.050 -
- ND ND
- ND ND
- 0.012
- 0.005 -
- ND ND
- 0.010 -
- ND ND
Total PPIX 42.58 0.060
aWhole blood volume = 55.6 ml kg- ' body weight. Plasma
volume = 38.8 ml kg-Ibody weight. Erythrocyte volume =
16.8 ml kg-' body weight. -, Below detectable levels. ND, not
determined.
Photodegradation studies were carried out to determine the
degree of degradation of the drug caused by the treatment,
and the possible reloading of the papilloma over time via the
circulating plasma. This would be ofimportance for decisions
on the time schedule for possible fractionated or repeated
treatments in the future. Biopsies from irradiated and control
papillomas were taken at 15 min and at 1, 2, 3 and 4 h after
light exposure of 60 J cm-2. The concentration of drug was
measured in all 10 papillomas. The irradiated papillomas
contained an average of 41% of the amount found in the
3-
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Figure 2 Skin damage as a function of light dose. Ordinate
scale: mean values of arbitrary units (0= no damage; I = slight
damage; 2 = moderate damage; 3 = severe damage). Bars = Stan-
dard deviation. The injected doses of ALA were: 50mg kg-
(X), 100mgkg-I ( 1), 200mgkg-I (_).non-irrasdiated papillomas at each time point up to and in-
cluding the 4 h samples, with 59% of the drug apparently
eliminated from the treatment sites (data not shown).
Efficacy
Initial responses to PDT with ALA were varied (Figure 3).
The initial response did not always reflect the long-term
response (end result after 3 months), which was our measure
ofefficacy. Pattern 'a', seen in 26% ofthe treated papillomas,
was a complete response. The lesions disappeared and did
not recur during the 3 month follow-up. This pattern was
usually obtained within 10 days after treatment. Pattern 'b',
seen in 36% of the papillomas, began with a total or near
total decrease in volume, followed by regrowth beginning on
or about the tenth day after treatment. Pattern 'c', the initial
response pattern of 20% of the papillomas, was characterised
by an immediate reduction in papilloma size that was usually
greater than 50%, followed by regrowth to a volume that
6000
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Figure 3 Variability of papilloma response patterns after treat-
ment. Solid circle, response 'a' (complete regression); open circle,
response 'b' (near total reduction in size followed by regrowth,
with size at 3 months less than or equal to original size); solid
triangle, response 'c' (partial reduction in size with regrowth to
size similar to initial papilloma); open triangle, response 'd' (less
than 50% reduction in size, with regrowth to a greater size than
initial).
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approximated the original papilloma. Pattern 'd', in 12% of
papillomas, was a partial decrease in size followed by a
relatively rapid increase in size, with the final papilloma
larger than before treatment. The initial response of rapid
decrease in size during the first week was in contrast to
response after treatment with m-THPC, where the papilloma
shrinkage occurred more gradually over a few weeks and
there was no regrowth of the papilloma during the full 3
month follow-up (Lofgren et al., 1994).
The efficicay of PDT with ALA, measured 3 months after
treatment, is shown in Table II. Two papillomas were treated
with 50mgkg-' ALA and a light dose of 160Jcm2. One
had a complete response, one a partial response (data not
shown). No further treatments were done at this light dose
because of potential damage to surrounding normal skin (see
Figure 2). Raising the light dose from 40 to 60Jcm-2 in-
creased the complete response rate from 19.4% to 37.8%,
while increasing the drug dose from 100mgkg-' to 200mg
kg-' did not appear to improve response. However, it was
clear from evaluation of the data that other parameters
beside light and drug dose affected response. These para-
meters included papilloma height and papilloma volume.
There was a clear pattern of reduced response with inc-
rease in papilloma height (Table III), probably reflecting the
ability of the light to penetrate to the base of the highly
keratinised papillomas. There was no improvement when the
ALA dose was increased. Correcting the light dose respbnses
for height of papillomas markedly reduced the difference
between 40 and 60 Jcm-2, but did not completely eliminate
it (30% for 40Jcm-2 vs 37% complete response for lesions
less than 8 mm high, if the data for the two drug doses at
60 J cm-2 are combined). Combining the drug and light dose
data, complete response was 35% for papillomas less than
8 mm in height, 22% for papillomas of 8-12 mm and 7% for
papillomas greater than 12mm in height.
Increasing volume of the papillomas, which reflects both
diameter as well as height, also showed a pattern of poorer
response (Table IV). Again, even though the number of
papillomas in some of the categories was relatively small,
there was the suggestion that 60 J cm-2 was slightly better
than 40Jcm-2, with no improvement with increased drug
dose. Complete response was 67% for all papillomas with a
volume less than 500 mm3, 27% for those between 500 and
1000 mm3, 10% for those between 1000 and 5000 mm3, and
9% for those greater than 5000mm3. It is very clear from
Table H Efficacy of ALA phototherapy as a function of light and drug dose
Response to treatment
Complete response Partial response No response
Drug and light doses Number % Number % Number %
100mgkg-l ALA
40 Jcm-2 14/72 19 4/72 6 54/72 75
100mgkg-X ALA
60Jcm-' 14/37 38 11/37 30 12/37 32
200 mgkg-' ALA
60 Jcm-2 12/45 27 5/45 11 28/45 62
CR, complete response; PR, partial response; NR, no response. Response was
determined 3 months after treatment.
Table HI Effect of papilloma height on PDT efficacy
Drug and Height CR PR NR
light doses (mm) Number % Number % Number %
lOOmgkg-' <8 6/20 30 1/20 5 13/20 65
40Jcm2 8-12 7/32 22 3/32 9 22/32 69
> 12 1/20 5 0/32 0 19/20 95
lOOmgkg' <8 11/25 44 5/25 20 9/25 36
60 J cm-2 8-12 3/12 25 6/12 50 3/12 25
>12 0 - 0 - 0 -
200mgkg-' <8 10/32 31 4/32 13 18/32 56
60 J Dn-2 8-12 1/6 17 1/6 17 4/6 67
> 12 1/7 14 0/7 0 6/7 86
CR, complete response; PR, partial response; NR, no response.Photodynamic therapy using injected ALA
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Table IV Effect of papilloma volume on PDT efficacy
Drug and Volume CR PR NR
light doses (mm3) Number % Number % Number %
100mgkg-' <500 2/4 50 0/4 0 2/4 50
40 J cm-2 500-1000 4/11 36 0/11 0 7/11 64
1000-5000 6/41 15 4/41 10 31/41 75
>5000 1/16 6 0/16 0 15/16 94
100mgkg- <500 5/8 62 1/8 13 2/8 25
60Jcm-2 500-1000 3/13 23 4/13 31 6/13 46
1000-5000 5/16 31 6/16 38 5/15 31
>5000 0 - 0 - 0 -
200 mg kg- <500 7/19 37 3/19 16 9/19 47
60Jcm 2 500-1000 2/9 22 2/9 22 5/9 56
1000-5000 1/10 10 0/10 0 9/10 90
>5000 1/7 14 0/7 0 6/7 86
CR, complete response; PR, partial response; NR, no response.
these data that size and height of the papillomas alter res-
ponse to PDT.
We noted that papillomas of similar size, treated with the
same light and drug dose, showed variable response from one
rabbit to another. We therefore evaluated the effect of
plasma PPIX concentration at time of PDT (Table V). For
this analysis, the total number of papillomas evaluated was
fewer, since there was no plasma PPIX data on two rabbits.
Independent of papilloma size or light dose, there was a
marked difference in the response to PDT. Interestingly, the
plasma concentration ofPPIX did not correlate with the dose
of ALA injected. The mean plasma levels were 423 ± 323 lAg
ml1' and 350 ± 351 pgml-l for rabbits receiving 100mg
kg'- and 200 mg kg-' respectively. In fact, the rabbit with
the highest plasma level (1080 jig ml-') received 100mg kg-'
ALA. The lack of correlation between plasma PPIX levels
and ALA dose is most likely the reason why efficacy did not
correlate with ALA dose.
If we optimise the three major factors, papilloma height
less than 8 mm, volume less than 1000 mm3 and plasma
concentration of PPIX at the time of treatment greater than
5OO,gmm1', the efficacy results are impressive (Table VI).
More than 85% of the lesions showed either a partial or
complete response, with nearly 82% complete response. For
this analysis, we combined the two lower categories of papil-
loma volume (<500 mm3 plus 500-1000 mm3), since the
results were similar to the results with only the more strin-
gent volume restriction and the total number of papillomas
available for analysis was greater. Since CRPV-induced
papillomas never recurred spontaneously after an observation
period of 6 weeks if a complete response was achieved, this
81.8% value can be considered a cure rate.
Discussion
This study has shown that a long-term complete response
rate of 82% could be accomplished with intravenous ALA
PDT. To achieve this high rate, however, was a multistep
process. The investigation began with a complete kinetic
study of PPIX loading and elimination in papilloma, normal
skin and plasma, continued with a complete biodistribution
study, branched into a skin tissue tolerance to treatment test
that evaluated the acceptable light dose to healthy tissue at
various drug levels and time intervals, and finally culminated
in a full long-term efficacy study at the optimal conditions
defined by each step.
We were concerned about the fact that long-term studies
had demonstrated an unacceptable high recurrence rate for
basal cell carcinoma topically treated with ALA (Cairnduff et
al., 1994). This, however, might have reflected insufficient
penetration of the topically applied drug to all parts of the
tumours. We reasoned, therefore, that a systemically admin-
istered sensitiser might be far more efficient. ALA can be
administered systemically by either an intravenous or oral
route, the only known photosensitising anti-tumour agent
Table V Effect of plasma PPIX levels on ALA PDT efficacy
Response to treatment
Complete Partial
Plasma PPIX response response No response
levels Number % Number % Number %
<500 Lgml' 9/91 10 14/91 15 68/91 75
>500 .Lgml-' 27/38 71 6/38 16 5/38 13
Plasma levels of PPIX were determined 3 h after injection ofALA,
at time of PDT.
Table VI Efficacy of ALA phototherapy with optimised tissue and
plasma parameters
Response to treatment
Complete response Partial response No response
Number % Number % Number %
18/22 81.8 1/22 4.5 3/22 13.6
Optimal tissue parameters: plasma concentration of PPIX at time
of PDT >500 tgml-', papilloma height <8 mm, total volume of
papilloma < 1000 mm3.
with this property. The concept of administering a photosen-
sitising drug orally is intriguing, and could be ofconsiderable
practical importance in a clinical setting (Grant et al., 1993;
Loh et al., 1993). We have chosen systemic administration by
intravenous injection as opposed to oral administration, to
eliminate the problem with variation in absorption from the
gut. We knew (Lofgren et al., 1994) that there would be a
fair chance of variations in plasma and tissue concentrations
between different individual animals of the same size, species
and strain, even if all were given the same amount ofinjected
photosensitiser per kg body weight. By using intravenous
administration of the drug immediately after neutralisation, a
high concentration of PPIX can be achieved without pain at
the injection site. In patients we would expect intravenous
delivery to prevent systemic symptoms such as vomiting,
which sometimes occurs after oral administration. Malnutri-
tion is not uncommon in patients with tumours and this
would also complicate oral administration.
Tumour photodestruction using ALA, which converts to
PPIX, is achieved by inducing (for a very short time) a well
known disease-erythropoietic protoporphyria (EPP).
Patients with erythropoietic protoporphyria acquire lesions
attributable to light exposure. Although troublesome, the
disease rarely causes severe or deforming scarring (Anderson,
1990). It seems unlikely that one or even a limited number of
administrations could induce the liver disease found in a
minority of patients with EPP. In fact, liver function is
usually normal in EPP, sometimes even when protoporphyrin
in the liver appears to be considerably increased (Anderson,
1990). Systemic bolus administration of ALA will give tissue
levels of PPIX that could cause tissue damage but only for avery short period, during which time the patient can be
protected from light.
Although this study was not designed to study toxicity, it
should be noted that none of the 21 rabbits given ALA at
50-200 mg kg-' body weight incurred any general symptoms
of toxicity, i.e. weight loss or skin reaction. A single addi-
tional rabbit given a high dose of ALA (300 mg kg-')
developed a porphyric reaction with red skin for several days,
followed by scaling of the skin and a dry pelt for 4 weeks.
The skin healed completely, and the two very large treated
papillomas disappeared and did not return during the 3
month follow-up.
Successful PDT is dependent on a number of parameters
that must be evaluated for the individual patient. Among
these parameters is the size of the lesion, which presumably
reflects limitation of light penetration to all cells within the
tumour. We have also identified another critical factor. In
this study, as well as in a previous study of m-THPC (Lof-
gren et al., 1994), the concentration of the photosensitiser in
plasma at the optimal treatment time (the time point when
the ratio between drug concentration in papilloma and nor-
mal tissue is largest) had a significant impact on, or was a
predictive marker for, the final outcome. Plasma concentra-
tion might be one explanation for variable clinical responses
with previously used sensitising drugs. This can possibly be
addressed in a clinical situation by analysing the PPIX con-
centration in plasma (a simple 5 min procedure) immediately
before light exposure. It is possible that low values could be
compensated for by increasing the proposed light dose, and
vice versa for high plasma values. Our findings of a minimum
necessary plasma concentration do not imply that treatments
would be more effective if they are carried out when the
plasma level peaks. This might result in an effective tumour
necrosis, but would probably damage surrounding normal
tissue.
It has been known for some time that tissues incubated in
vitro with ALA vary in their conversion to PPIX (Sardesai et
al., 1964). There is evidence to support the hypothesis that
the content of ferrochelatase is low in tumour tissue, possibly
being one of the factors responsible for the selectively higher
concentration of PPIX (and- other porphyrin-related
photosensitisers) in tumours compared with most other tis-
sues (Dailey and Smith, 1984). The conversion of human
breast tissue explants is about five times more efficient in
tumour tissue than in normal tissue (Navone et al., 1988),
correlating well with our findings. We also found that con-
version efficiency varied in different tissues in vivo. Defining
safety parameters for correct drug and light dose-a task
that, in man, is often very difficult to carry out-can be
approximated from animal tissue distribution studies. These
data would suggest that some normal tissues (i.e. liver) would
be at higher risk of ALA-PDT damage than others.
The extraction procedure we used in this study and our
previous study of m-THPC (Lofgren et al., 1994), showed
higher PPIX levels in muscle than in mucosa. Others have
measured PPIX by fluorescence in vivo (Pottier et al., 1986),
and several studies using fluorescence microscopy have found
higher levels in mucosa than muscle (Bedwell et al., 1992;
Peng et al., 1992; Loh et al., 1993). We do not have a
definitive explanation for this difference, but can speculate on
possible reasons. A higher level in epithelial cells might be
expected with topical application, where the ALA first con-
tacts the epithelium. With systemic application, either
parenteral or oral, the difference is less obvious. However,
those studies were done in mice and rats and ours was done
in rabbits. It is very possible that the distribution differs with
species. In addition, the fluorescence signal would only be
detected from the superficial surface of intact tissue, while
our extraction process analyses the whole biopsy. Our extrac-
tion process is at least 92% efficient (see Materials and
methods). The ability to recover such a high level of PPIX
from skin confirms that epithelial tissue does not show a
preferential reduction of exogenously added PPIX.
It must be recognised that there are major differences in
mechanisms of distribution between different photosensitising
Photodynamic therapy using injected ALA
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agents. A photosensitiser such as m-THPC comes close to a
'hard drug', which is minimally metabolised before excretion.
ALA, in contrast, is a precursor to the active drug, which is
synthesised more in some tissues than in others. The active
substance is also possibly detoxified largely by a local
mechanism by insertion of an iron atom in the molecule,
whereas m-THPC more likely is excreted in its original form
after conjugation to macromolecules by the liver. Therefore,
such biodistribution studies must be determined for each
drug of interest.
Interspecies dose equivalency is an important factor in
translating therapeutic results and toxicity in animals to
predicted results in man. Using our measured average rabbit
skin size of 0.14m2, the following calculations can be made.
The Km factor, the ratio of surface area to mass that permits
conversions of dosing relationships from one species to
another (Spector 1961; Mellet 1969; Van Miert 1986), can be
calculated to be 15.7 for rabbits, given a mean measured
body weight of 2.2 kg and surface area of 0.14 m2. Multiply-
ing a dose in mg kg-' by the Km factor gives the correspon-
ding dose in mg m 2, e.g. 50 mg kg-' for rabbit will translate
to 785 mg m-2. To convert from dosages determined in
animal studies to a dosage in man, all that is needed is the
ratio of the relevant Km factors. A human adult weighing
60 kg has a Km factor of 37.5 (Van Miert, 1986). Thus
Kmman . Kmrabbit=37.5 + 15.7=2.38, and a man would re-
quire a drug dose 1 2.38 (42%) as much as the rabbit. For
the doses used in this study, equivalent doses in man would
be 21mgkg-1, 42mgkg-' and 84mgkg-l (13.1 mgm-2,
26.3 mg m 2 and 53.4 mg m-2). Note that this calculation
may only be used as a rough guide and not as a recom-
mended dose. The metabolic equivalency in relation to other
species, including man, can also be estimated by using the
assumption of three-quarter power proportionality of body
weight (Van Genderen 1975, Van Os 1982; Van Miert 1986),
again only as a rough guide.
The photodegradation experiment carried out in this inves-
tigation demonstrated that the concentration of PPIX is
significantly reduced (60%) after irradiation with treatment
levels of light, i.e. 40-60 Jcm-2. This reduction in concentra-
tion persists for several hours, in contrast to the same situa-
tion after injection with m-THPC (Ronn and Lofgren, 1994).
The difference was also visually apparent because the treated
surrounding skin was blanched by treatment with ALA as a
photosensitiser, whereas no immediate change in skin colour
was usually observed using m-THPC under similar irradia-
tion conditions (30-40 J cm-2). The cause of the decreased
concentration is most likely both a photodegradation or
bleaching of the drug itself and a persistent closure of the
microcirculatory perfusion of the treated papilloma, preven-
ting reloading of drug and oxygen. We cannot, however, rule
out other mechanisms, such as a direct effect on the biosyn-
thesis responsible for the production of PPIX.
In sum, the overall long-term efficiency of papilloma des-
truction after a single treatment of ALA-PDT is surprisingly
high (82%), provided that the above outlined factors are
addressed. Taking into consideration the short required inter-
val between administration and treatment and the almost
total elimination of active drug within 24 h, we believe that
further evaluation of this treatment modality by clinical
phase I and II trials is indicated.
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